However, another glutamine transporter inhibitor, V-9302, selectively blocks glutamine uptake in triple-negative breast cancer (TNBC) cells but not CD8+ T cells, thereby improving CD8+ T cell effector function Figure 1A (99). This evidence concerns the gene CD8A and triple-negative breast carcinoma.